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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
tryptophan is effective in improving sleep in healthy individuals with mild sleep disorders. 
STUDY DESIGN: Systematic review of three published, randomized controlled trials (double-
blind, placebo-controlled) between 2005-2010, all English language.  
DATA SOURCES: Three randomized controlled trials published between 2005 and 2010 were 
found using PubMed/MEDLINE and Cochrane databases.  
OUTCOMES MEASURED: Improved sleep quality and duration of sleep, which were measured 
using sleep diaries and sleep study questionnaires.  
RESULTS: The first study, Cubero et al showed that administration of diet containing high 
levels of tryptophan reflected more hours of sleep (~7.68 h) as compared to the control (~6.77 h). 
Hudson et al report a 13.3% increase in total sleep time with pharmaceutical tryptophan added to 
carbohydrates as compared to 5.5% increase in total sleep time with foods that have naturally 
high content of tryptophan. The duration of sleep measured in the Shell et al study showed an 
increase of 6.83 h as compared to 5 h in the control group. No serious adverse events were noted 
in any of the three studies. 
CONCLUSIONS: All three studies reported increases in the duration of sleep and improved 
sleep quality when tryptophan was included in each trial. This suggests that indeed tryptophan is 
effective in improving sleep in healthy individuals with mild sleep disorders with little adverse 
reactions from the added tryptophan. 
KEY WORDS: Tryptophan, sleep
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INTRODUCTION 
Sleep disorder is characterized by an interruption in one’s sleep pattern in which an 
individual gets little to no sleep (less than 7-8 hours) due to the difficulty in initiating or staying 
asleep – specifically insomnia.1 Those with mild sleep problems are those categorized as “short-
term” where symptoms last 1-3 weeks.2 This paper evaluates three randomized control trials 
(RCTs) comparing the efficacy of tryptophan in improving sleep in healthy individuals with mild 
sleep disorders. 
Sleep disorders are relevant to patients because about 70 million people have some form 
of sleep disorder which affects their functional daily activities.
1
 As a result, they become sleepy 
during the daytime, which leads to loss of productivity at school, work, home, increased risk of 
getting into accidents while on the road, and increased risk of other chronic health problems.
3
 
Studies show that close to 20 percent of motor vehicle accidents are due to drivers who have not 
had adequate sleep.
3
  Others experience work-related injuries due to day-time sleepiness and 
significant fatigue.
3
  
 Its relevance to the Physician Assistant is due to the increasing number of health care 
visits each year for sleep problems – about 137 percent increase in those who suffer from 
insomnia. A significant number of physicians have reported an increase in health conditions with 
those who complain of sleep problems, mainly “hypertension; diabetes; depression; and 
obesity”.4 And since many of these clinicians do not have certification to bill for pertinent sleep 
studies in their offices or lack the necessary training to interpret the results, they are unable to 
provide a continuum of care even after these patients have seen specialists.
 
There is an increase 
need to include sleep testing in the offices and appropriate certification or training to physicians 
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and Physician Assistants since it is affordable, efficient and has shown to improve follow-up 
time with patients who present with sleep problems.
 4
 
  The exact cost of sleep disorders is unknown; however studies suggest that about 
“billions of dollars are spent each year in the United States on the direct costs of sleep loss and 
sleep disorders.” 3 This is partly due to increase use of healthcare facilities for hospital 
procedures, prescriptions, and office visits. On average, laboratory sleep-tests for those with 
sleep problems may cost about “$17.5 billion to test and $3 billion to treat every person in the 
United States”. 3 Studies show that close to $1.2 billion was attributed to sleep aids for insomnia 
in 2002 and there is a significant increase in cost for elderly patients seeking care for their sleep 
problems.  Other indirect costs include absent from work or school, incapacity, health conditions, 
late work schedules, medication abuse, accidents at work or on the road, and much more.  All of 
these factors affect total expenditure in the US and is concerning to both the consumer and 
producer.
3
 
 Though the main cause of sleep disorders is unknown, it is believed to be 
“multifactorial” where individuals have medical, mental or physical problems. 2 Some of the 
medical problems include obesity, hypertension, chronic obstructive pulmonary disease, and iron 
deficiency.
1
 Mental problems include anxiety disorders, depression, bipolar or psychosis.
2
 Some 
physical problems include irregular bed times, activities around bedtime, and other daytime 
activities.
2
 Some usual methods used to treat sleep disorders include “benzodiazepines (trizolam, 
estazolam, lorazepam), nonbenzodiazepine sedatives (zaleplon, zolpidem, eszopiclone), 
melatonin agonists (ramelteon), and antidepressants (doxepin, amitriptyline and trazodone).”5 
Other nonpharmacologic ways include modified sleep actions, relaxation techniques, cognitive 
therapy and cognitive behavioral therapy.
5
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Tryptophan is an amino acid that is found in most foods rich in protein and some plants. 
Once metabolized in our bodies, it is converted to serotonin and melatonin and this shortens the 
time to fall asleep and prolongs sleep duration.
6
 The treatment options mentioned above all play 
an effective role in treating sleep disorders. However, as with all medications, each option will 
have a different effect on each patient. The use of foods containing tryptophan or incorporating 
pharmaceutical tryptophan into foods can be effective in improving sleep in healthy individuals 
with mild sleep disorders. 
OBJECTIVE 
 The objective of this systemic review is to determine whether or not “tryptophan is 
effective in improving sleep in healthy individuals with mild sleep disorders.” 
METHODS 
 Three double-blind randomized controlled trials were used in this review. The population 
was limited to pre-weaning infants of 4-20 weeks in age; and males and females older than 18 
but younger than 65 years of age, all showing some sleep problems related to insomnia. The 
intervention for the first two RCTs included food containing varying amount of tryptophan in 
them and the last one was with amino acid capsules filled with 5-hydroxytryptophan. The 
specific concentration and sources of tryptophan intake varied across studies, as did the structure 
of each control group. Comparisons were made between the treatment groups and an 
experimental group who received a visually matched placebo or control. Outcomes measured 
included quality of sleep and duration of sleep. 
 Key words used in the search included Tryptophan and sleep. The chosen articles were 
all written in English and published between 2005 and 2010. Each was found through PubMed 
and Medline databases and selected based on their relevance to my clinical question and whether 
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they included Patient-Oriented Evidence that Matters (POEMS). The inclusion criteria consisted 
of randomized controlled trials and a population of healthy individuals 4-20 weeks of age and 
18-65 years old, all with mild sleep disorders. Those excluded from the studies were infants 
older than 20 weeks, adults with heart disease, mental health disease, diabetes, sleep apnea, food 
allergies, endocrine disease, implanted pacemakers or electrical devices, those taking 
prescription sleeping medication or have taken Gabadone, pregnant women or lactating mothers, 
and shift workers. Summary of statistics reported include p values, analysis of variance 
(ANOVA) with Scheffe F-test scores, multivariate analysis of variance F-score (MANOVA), 
RRR, ARR and NNT values. Table 1 summaries the demographics included in each study. 
Table 1: Demographics & Characteristics of included studies 
Study Type # of 
pts 
Age(yrs) Inclusion criteria Exclusion criteria W/D Intervention 
Cubero, 
(2007)
7 
Double 
blind 
RCT 
30 4-20 
weeks 
Patients were at 
least 5 months of 
age with sleep 
problems (more 
than three 
nocturnal 
awakenings) 
Infants > 20 weeks 0 Diet C: Blemil 
Plus 1 Day (low 
L-tryptophan 
levels)  and 
Blemil Plus 1 
Night (high L-
tryptophan 
levels) 
 
Hudson, 
(2005)
6 
Double 
blind 
RCT 
57 >18 Patients with 
difficulty 
initiating or 
maintaining 
sleep three or 
more 
nights/week for a 
duration of three 
months or more 
Heart disease, mental 
health disease, 
pregnancy, food 
allergies, diabetes, 
sleep apnea and shift 
workers 
8 Protein source 
tryptophan and 
pharmaceutical 
grade 
tryptophan in 
combination 
with 
carbohydrate 
 
Shell, 
(2010)
8 
Double 
blind 
RCT 
18 18-65 Patients with a  
history of 
intermittent 
nonrestorative 
sleep 
Patients currently 
taking prescription 
sleeping medication, 
those who have 
previously taken 
Gabadone, those with 
known endocrine 
disease, pregnant or 
lactating females and 
those with implanted 
pacemakers or 
implanted electrical 
devices. 
0 Gabadone ( a 
combination of 
5-
hydroxytryptop
han, GABA and 
choline in low 
dose) 
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OUTCOMES MEASURED 
 The outcomes measures in all three studies were POEMS using daily sleep diaries or 
sleep evaluation questionnaire. In Cubero et al.’s study, the children in the treatment group were 
fed with Diet C, which was made of Blemil Plus 1 Night – 3.4 g of tryptophan in 100 g of 
protein and Blemil Plus 1 Day – 1.5 g of tryptophan in 100 g of protein.”7 The parents of the 
children undergoing the experiment were instructed to log their children’s sleep pattern over 24 
hours, the number of bottles they had, and any occurrence that ensued that night in daily sleep 
diaries. Also, actimeters were put on the children’s ankles to quantify their movement while 
asleep in order to correlate them with their parents’ sleep diaries. These actimeters stored any 
change the child made every two minutes and were analyzed immediately after it came off by the 
“Sleep analysis software” based on “actual time of nocturnal sleep, minutes of immobility of the 
infant in its cradle during the night, sleep latency, percentage of nocturnal awakenings and sleep 
efdeciency.
7
 Hudson et al. experimental group received food containing “250mg of 
pharmaceutical tryptophan with 25 g of dextrose and 25 g of rolled oats (Food 2)” and food 
containing “25 mg of derailed butternut squash seed meal and 25 mg of dextrose (Food 1).”6  
Subjects in this group utilized sleep diaries as well, where the total sleep time; sleep efficiency 
(time asleep/total time in bed X 100); time awake during night; time awake during middle of 
night was recorded. Sleep quality index, which included perception of rejuvenation in morning 
(1 = Exhausted, 2 = Fair, 3 = Refreshed) and perception of sleep quality (1 = Restless, 2 = Fair, 3 
= Very sound) were averaged out using the aforementioned subjective measures to create scores 
to help with consistency.
6
 Lastly, Shell et al.’s treatment group received capsules with Gabadone 
in it, which included 5-hydroxytryptophan among other substances in a capsule. Subjects 
completed both the Pittsburgh sleep quality index (PSQI) and the Leeds Sleep Evaluation Visual 
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Analog Scale (LSEQ). The LSEQ questionnaire included “1) falling asleep; 2) quality of sleep; 
3) ease of waking from sleep; and 4) behavior after awakening”.8 The PSQI  included subjective 
information like “bedtime, rising time, minutes to fall asleep, and actual hours slept.”8 
RESULTS 
 Three double-blind randomized controlled trials compared the effects of sleep in 
individuals that showed some sleep problems with varying amounts of tryptophan in their food 
and one trial was with capsules. Cubero et al. studied children 5 months old or younger with 
some sleep difficulties in their own respective homes. Compared to the treatment group, the 
control group received normal initiation milk (Blemil Plus 1 Forte – Diet A) without any 
addition of tryptophan. All thirty enrolled children were followed for 3 weeks and both clinician 
and subjects were kept blind to the study.  Data from this trial was reported as continuous data 
that was later converted into dichotomous format to evaluate tolerability and treatment effects. It 
was noted that the children who received Diet C showed major improvement in their total time 
asleep as compared to the control – Diet A (p<0.05). When evaluating the treatment effect of 
Diet A versus Diet C the RRR was 3.42, ARR was 0.41 and NNT 2.439. No side effects were 
reported by the parents of children who were involved in this experiment. 
Table 2: Cubero et al. treatment v. control ANOVA with Scheffe F test at 3 weeks (X ± SD) 
 Daily hours of actual 
sleep 
Nocturnal sleep latency 
(hours) 
Sleep improvement % 
as reflected in the 
responses to the 
questionnaire given by 
parents of infants 
Diet A (control) 6.77 ± 0.12 0.60 ± 0.08 12 
Diet C (high tryptophan) 7.68 ± 0.54 0.44 ± 0.04 53 
  
 Hudson et al. studied 57 male and females older than 18 years of age who showed 
symptoms of primary insomnia and could complete the protocol for 3 weeks. Subjects met with 
  Asante-Odame, Tryptophan and Sleep     7 
 
the nurses at the various hospitals to turn in their sleep diaries and review side effects.  Data from 
this trial were reported as continuous data and could not be converted into a dichotomous format; 
therefore calculations evaluating tolerability and treatment effects could not be computed. 
Hudson et al. reported that eight subjects dropped out of the study due to “failure to attend 
weekly interviews, death of close family member, relationship stress, and nausea”.6 These 
subjects’ data were not included in the final data analysis. Compared to the treatment group, the 
control group received Food 3 which only had 50 g of rolled oats. Subjects who had either Food 
1 or Food 2 showed increase in total sleep time (5.5% with a p<0.10 and 13.3% with a p<0.01, 
respectively) as compared to Food 3, which was insignificant. Pairwise comparisons were 
reported between weeks using the MANOVA test and are listed in Table 3. Also, only three 
patients out of the 57 individuals who enrolled in the trial reported having nausea mainly from 
Food 1 and Food 3. 
Table 3: Hudson et al. Pairwise Measurements for Treatment v. Control groups 
 Total sleep time in 
minutes (baseline 
week) 
Total sleep time in 
minutes (treatment 
week) 
Sleep efficiency 
(time asleep/time 
in bed)% 
Sleep quality index 
(1-low, 2-average, 
3-high) 
Food 1 339 ± 15.1 358 ± 15.1 74.0 ± 2.77 2.02 ± 0.096 
Food 2 314 ± 16.0 356 ± 16.0 74.7 ± 2.94 2.08 ± 0.102 
Food 3 359 ± 16.6 376 ± 16.5 76.9 ± 3.03 1.78 ± 0.106 
 
 Shell et al. studied patients between 18 to 65 years of age with a history of intermittent 
nonrestorative sleep for a week. All the data from the trial was continuous data that could not be 
converted to dichotomous data. Eighteen patients were randomly selected and baseline 
elctrocardiographic measurements were recorded. Half were assigned to either take two capsules of 
Gabadone before bed or two capsule of placebo before bedtime.  Sleep study questionnaires and 
electrocardiographic analysis were created from the results after day 7. A significant 
improvement in time to fall asleep was achieved in subjects who took Gabadone, about 41% with 
  Asante-Odame, Tryptophan and Sleep     8 
 
a p=0.01. Also, subjects in the treatment group had about one extra hour of sleep (p=0.01) as 
compared to the control group who did not see any significant change in the duration of sleep 
(p=0.46). Shell et al. reported that none of the subjects complained of side effects from either 
taking placebo or Gabadone. Table 4 summaries the variables imperative to this review paper. 
 
Table 4: Shell et al. treatment v. placebo LSEQ and PSQI computed data 
 Gabadone Placebo 
 Baseline Day 7 Baseline Day 7 
Time to sleep 
(mins) 
32.32 19.11 34.83 33.11 
Hours slept 5.00 6.83 7.17 7.11 
Am grogginess 
(mins) 
30.56 11.11 67.78 65.00 
Perceived snoring 
reduction, % 
25 Not significant 
  
DISCUSSION 
 Using three double-blind RCT’s, this meta-analysis reviewed the effect of tryptophan in 
improving the sleep in children between 4-20weeks of age and adults between 18 and 65 years 
old with mild sleep disorders. The blinding and validity of each RCT was without error, with 
very few drop-out rates, however sample sizes were relatively small as were follow up duration. 
In addition, the effects of tryptophan on sleep were only assessed via computed data from 
subjects’ responses in the different questions, however many other options exist. Though Cubero 
et al.’s trial focused on children less than 5 months of age, the other two studies mentioned in 
this review have shown benefit to using tryptophan in individuals older than 18 but younger than 
65.  
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 Tryptophan (mainly known as L-tryptophan) is an essential amino acid that is relatively 
safe when used as directed. Its supplementation is contraindicated in patients taking 
antidepressants or other sedatives as this may cause profound drowsiness. The Food and Drug 
Administration (FDA) regulates the sale of tryptophan since it was reported to have caused a 
deadly condition called eosinophilia-myalgia syndrome (EMS) in 1989. And though there have 
not been any significant incidences of this condition since, many pharmaceutical companies are 
required to label all ingredients on their packaging. There are not enough studies to determine the 
appropriate dose for tryptophan and no black box warning exists.
9
 
 Tryptophan supplementation has other uses: premenstrual dysphoric disorder (PMDD), 
smoking cessation, bruxism, facial pain, depression, seasonal affective disorder and anxiety. 
Nevertheless, more research is needed to validate this aforementioned uses.
10
 Not only is it 
necessary that sample sizes be large or longer research trials be conducted; it is also important to 
determine the appropriate length of time to take this supplement  as there is very little research 
about dependence or withdrawal syndromes. Also, certain criteria should be in place to identify 
reliable pharmaceutical companies who do not genetically engineer L-tryptophan because this 
can pose a risk to the development of EMS. 
CONCLUSION 
 Based on the three studies above, it can be concluded that tryptophan is effective in 
improving sleep in healthy individuals with mild sleep disorders. When added to various food as 
a supplement or taken in a capsule form, tryptophan consistently lower the time to fall asleep and 
lengthen duration of sleep in people who present with sleep problems as compared to the group 
who did not take it. 
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